ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2015
The financial hazard of personalized medicine and supportive care.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Experiences accessing and receiving tumour genetic profiling in Victoria: a consumer-led cross-sectional survey study.BMC cancer · 2026Article
- Associations of Financial Toxicity with Employment Concerns and Cancer-Related Distress: A Cross-Sectional Survey among Korean Working-Age Cancer Survivors.Cancer research and treatment · 2025Article
- Cancer-associated financial burden in German head and neck cancer patients.Frontiers in oncology · 2024Article
- Assessing suffering of patients on cancer treatment and of those no longer treated using ESAS-Total Care (TC).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Race, Affordability and Utilization of Supportive Care in Ovarian Cancer Patients.Journal of pain and symptom management · 2022Article
- Cost-effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non-small cell lung cancer.Thoracic cancer · 2022Article
- Impact of objective financial burden and subjective financial distress on spiritual well-being and quality of life among working-age cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Italian version of the Edmonton Symptom Assessment System (ESAS)-Total Care (TC): development and psychometric validation in patients undergoing cancer treatment or follow-up.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Exploring healthcare providers' experiences with specialty medication and limited distribution networks.PloS one · 2022Article
- Understanding the strategies rural cancer patients and survivors use to manage financial toxicity and the broader implications on their lives.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Now we are 30: 10 more years of MASCC.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country.Iranian journal of pharmaceutical research : IJPR · 2021Article
- Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model.Thoracic cancer · 2021Article
- The validation of the Italian version of the COmprehensive Score for financial Toxicity (COST).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Supportive care in cancer-a MASCC perspective.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Review
- Targeting Financial Toxicity in Oncology Specialty Pharmacy at a Large Tertiary Academic Medical Center.Journal of managed care & specialty pharmacy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Personalized medicine is revolutionizing the delivery of oncological care, promising benefits both at the patient and health system levels. The cost of targeted therapies, unfortunately, is becoming more expensive and unaffordable. Where supportive care in cancer concerns the prevention and management of the adverse effects of cancer and its treatment and is the thrust of the Multinational Association of Supportive Care in Cancer, financing of and value in personalized medicine is an important area of research and engagement for the association. Discussing patients' concerns with and identifying those at most risk for the financial hazard of cancer treatment and offering financial counseling and assistance and/or referral to support networks are potential key areas for (exploring and providing) better supportive care. The time is now to turn the concern of patients and their carers, providers, and other advocates regarding the affordability of cancer treatment into a collective cause towards coordinated action.
Indexed as
Identifiers
26306523What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.